AB928 is primarily utilized in the field of medical research, particularly in the development of cancer therapies. It functions as a dual antagonist targeting specific receptors involved in immune regulation, which can help in modulating the tumor microenvironment. This makes it a promising candidate for enhancing the efficacy of immunotherapies by potentially reducing immunosuppression and promoting anti-tumor immune responses. Researchers are exploring its use in combination with other treatments to improve outcomes in various cancer types.